Angela Myers NextAvenue

Oct 7, 2024 | startribune.com | Angela Myers |Angela Myers NextAvenue

Kisunla’s manufacturer reports the drug can reduce cognitive decline by over 35% in 76 weeks in patients with early stage Alzheimer’s. The key, however, is that the drug works in the earliest stage. Budson outlines three criteria many doctors use to categorize early stage Alzheimer’s:Family, loved ones or a doctor have expressed concerns about impaired memory. The individual completes a cognitive function test, and the results demonstrate some cognitive impairment.